Recent Insights on the Medicinal Chemistry of Sickle Cell Disease
Abstract:Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. SCD is a genetic disease characterized by punctual mutation that basis on the exchange of glutamic acid to valine in a beta chain of hemoglobin. In deoxygenated state, the interaction among the beta chains leads to hemoglobin polymerization carrying out to deformation of cytoskeleton structure of red blood cells to a sickle shape. Currently, the treatment is performed with the antineoplasic drug hydroxyurea. This review summarizes current knowledge about possible targets and the approaches to discover new compounds to treat the SCD symptoms. Drug design based on therapeutical application and molecular modifications strategies will be discussed.
Keywords: Chelating agents; drug discovery; erythrocyte dehydratation; fetal hemoglobin; gardos channel; hemoglobin inducers; hemoglobin modifiers; hydroxyurea, nitric oxide; phytomedicines; sickle cell disease; sickle cell treatment; vasodilatation; vasodilation
Document Type: Research Article
Publication date: 2011-05-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.